Navigation Links
PacificGMP Completes GMP Product Fill for Trius Therapeutics
Date:5/14/2008

SAN DIEGO, May 14 /PRNewswire/ -- PacificGMP, the leader in utilizing single-use bioprocessing for development and manufacturing for its client partners, announced today that it has completed a product fill under GMP (good manufacturing practices) standards for a Trius Therapeutics Phase I clinical trial.

"We are pleased to have worked closely with Trius on this GMP fill project, an effort that we were able to initiate quickly and complete within a narrow deadline," said Leigh N. Pierce, president of PacificGMP. "Although our client base consists of mainly biologics drug developers, PacificGMP has completed projects for a variety of other customers including small molecule drug developers like Trius, as well as academic institutions and diagnostics companies."

"PacificGMP successfully completed our GMP product fill and I appreciated their flexibility and willingness to work with us to get the job done in a timely and professional manner," said Jeffrey Barker, Director of Pharmaceutical Development for Trius Therapeutics.

About PacificGMP

PacificGMP is a contract manufacturing organization (CMO) and industry leader in utilizing single-use bioprocessing for development and manufacturing of biologics. Single-use technology eliminates the risk of cross-contamination, has fewer system requirements and significantly reduces the time required to initiate production. Benefits to clients include rapid project turnaround and the most cost effective solution in the industry. PacificGMP provides cGMP and non-GMP services ranging from cell line optimization, early process design, development and scale-up, to preclinical and clinical biologics manufacturing, purification and fill/finish. More information can be found by visiting the Company's web site at http://www.pacificGMP.com.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens. The company's lead drug candidate, TR-701 is a novel, oral and IV, oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R). Trius has licensed worldwide rights outside of Korea to TR-701 from Dong-A Pharmaceuticals. Trius' pipeline includes two additional structure-based drug design programs directed against novel antibacterial targets. For more information, visit http://www.triusrx.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Leigh Pierce http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=67271

Contact:

PacificGMP

Gary Pierce

Chief Business Officer

858-550-4094


'/>"/>
SOURCE PacificGMP
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, ... John Greisch , Hill-Rom,s president and chief executive officer, is ... The live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm ... conclusion of the live event through September 13, 2017. ...
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
Breaking Medicine Technology:
(Date:6/23/2017)... Alexandria, VA (PRWEB) , ... June 23, 2017 ... ... short of what is needed and will ultimately do significant harm to people ... care to everyone. , "While it leaves in place the Affordable Care ...
(Date:6/23/2017)... ... June 23, 2017 , ... Yesterday, U.S. Senate Republicans ... to repeal and replace the Affordable Care Act (ACA). Like the bill narrowly ... to Medicaid, a public health insurance program for low-income children, pregnant women, parents ...
(Date:6/23/2017)... ... ... The Military Officers Association of America (MOAA) announced its support for the ... Col. Thomas G. Bowman. , Bowman currently serves as the staff director for the ... issues and challenges veterans face with the VA. Following a 30-year career of service ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend and ... to the JFK Virgin Atlantic lounge. , Bensko is no stranger to the ... ago, Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, her ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today announced the ... at 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). It is ... who owns three other locations in the Topeka and Bonner Springs, Kan. area. ...
Breaking Medicine News(10 mins):